Brief: Celltrion USA Announces Submission Of The Biologics License Application (BLA) Of Novel Subcutaneous Formulation Of Ct-P13 To U.S. Food And Drug Administration
Dec 22 (Reuters) - Celltrion Healthcare Co Ltd
091990.KQ :
* CELLTRION USA ANNOUNCES SUBMISSION OF THE BIOLOGICS
LICENSE
APPLICATION (BLA) OF NOVEL SUBCUTANEOUS FORMULATION OF CT-P13 TO
U.S. FOOD AND DRUG ADMINISTRATION
Source text for Eikon: ID:nBw4VY6l4a
Further company coverage: 091990.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Celltrion Healthcare Co
See all newsBrief: Celltrion USA says Ventegra Will Place FDA-Approved Biosimilar To Avastin , Vegzelma On Its Commercial Formulary As A Preferred Brand
Brief: Celltrion Healthcare To Acquire 92.7 Billion Won Worth Of Own Shares
Brief: Celltrion Healthcare Q3 Operating Profit 50.5 Billion Won, Down 30.4% From Year Earlier
Brief: Celltrion Usa- Announces Distribution And Incorporation Of Yuflyma (Adalimumab-Aaty) To Carepartners Specialty Pharmacy Cost Savings Programs
Brief: Celltrion Healthcare's Merger With Celltrion Approved In Shareholder Meeting -Yonhap